Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402.

Details

Language :

English

ISSN :

0732183X

Volume :

27

Issue :

27

Database :

Supplemental Index

Journal :

Journal of Clinical Oncology

Publication Type :

Academic Journal

Accession number :

105444803

Full Text :

https://doi.org/10.1200/JCO.2009.22.7066